Biocon-Mylan alliance leads the Herceptin biosimilar pack
This article was originally published in Scrip
Executive Summary
A clutch of Indian firms including Biocon, Dr Reddy's Laboratories, Intas Pharmaceuticals and Cipla are developing biosimilar versions of Roche's Herceptin (trastuzumab), raising the prospects of the potential launch of a cut-price version of the product on the domestic market.